The Fly | ABBV

Today

AbbVie price target raised by $20 at JPMorgan, here's why

ABBV

8:01 AM

AbbVie price target raised by $12 at Guggenheim, here's why

ABBV

7:26 AM

Tuesday

What You Missed On Wall Street On Tuesday

+26

Jul 7, 4:15 PM

Monday

Closing Bell Movers: Crinetics doubles on Vertex buyout

Jul 6, 7:33 PM

AbbVie cuts FY26 adjusted EPS view to $13.91-$14.11 from $14.08-$14.28

ABBV

Jul 6, 4:18 PM

AbbVie sees Q2 adjusted EPS ex-items $3.57-$3.61, consensus $3.77

ABBV

Jul 6, 4:17 PM

AbbVie says Q2 EPS to include unfavorable impact of 17c

ABBV

Jul 6, 4:16 PM

Genmab says EC grants marketing authorization for Tepkinly combo

Jul 6, 1:58 PM

AbbVie says Tepkinly combo approved by EC for lymphoma treatment

ABBV

Jul 6, 1:46 PM

AbbVie price target raised by $25 at HSBC, here's why

ABBV

Jul 6, 10:19 AM

AbbVie price target raised by $25 at Cantor Fitzgerald, here's why

ABBV

Jul 6, 7:04 AM

Over a week ago

House committee opens probe into Merck, AbbVie China drug trials, Reuters says

Jun 30, 10:04 AM

Genmab announces topline results from EPCORE DLBCL-4 trial

Jun 29, 4:20 PM

AbbVie reports 'positive' results from Phase 3 EPCORE DLBCL-4 trial

Jun 29, 4:17 PM

Regenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial

Jun 29, 7:18 AM

AbbVie announces CHMP opinion recommending approval of upadacitinib for AA

ABBV

Jun 29, 5:19 AM

AbbVie says FDA approves Skyrizi for pediatric use in psoriatic disease

ABBV

Jun 26, 4:53 PM

Apogee Therapeutics downgraded to Hold from Buy at TD Cowen

Jun 23, 5:41 PM

Apogee Therapeutics price target raised by $38 at RBC Capital, here's why

Jun 23, 8:20 AM

AbbVie's Allergan Aesthetics receives approval for Boey in Canada

ABBV

Jun 23, 8:01 AM

Apogee Therapeutics moved to No Rating at BofA

Jun 23, 7:26 AM

AbbVie price target raised by $8 at Canaccord, here's why

Jun 23, 6:55 AM

AbbVie announces European Commission approval for Skyrizi

ABBV

Jun 23, 6:07 AM

AbbVie announces European Commission approval of Maviret

ABBV

Jun 23, 5:58 AM

AbbVie announces EU approval of Skyrizi for pediatric patients

ABBV

Jun 23, 5:44 AM

Robust R&D Pipeline: Investment in innovative therapies across key therapeutic areas, fueling future growth.

Market-Leading Products: Portfolio includes top-selling immunology, oncology, and neuroscience treatments with significant market share.

Diversified Revenue Streams: Reduced reliance on a single product through successful new launches and strategic acquisitions like Allergan.

Biosimilar Competition Impact: Loss of market exclusivity for key products, particularly Humira, due to the entry of biosimilar competitors significantly impacting revenue and market share.

Pipeline Development Uncertainty: Failure to successfully develop, gain regulatory approval for, or commercialize new drug candidates and indications to offset revenue declines from mature products.

Regulatory Approval Delays: Delays or rejections from global regulatory authorities for new drug applications or expanded indications, hindering market entry and growth potential.